Citable filing context
SOLV's research view summarizes recent SEC filing context, starting with restructuring from Aug 5, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 5, 2026 | restructuring | Solventum announced its intention to separate its Health Information Systems business as part of a portfolio optimization strategy. |
| Aug 5, 2026 | earnings | Solventum reported second-quarter 2026 sales of $2.2 billion and increased its full-year 2026 financial guidance. |
| Jul 20, 2026 | management_change | Solventum appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026. |
| Aug 5, 2026 | Guidance: adjusted_eps | 7.10 to 7.20 |
| Aug 5, 2026 | Guidance: free_cash_flow | 200.00 to 300.00 |
| Aug 5, 2026 | Guidance: organic_sales_growth | 2.50 to 3.00 |
| Aug 5, 2026 | mda_quarterly | Solventum Corporation reported a 2.2% increase in second-quarter 2026 net sales to $2.2 billion, bolstered by $125 million in advanced customer orders ahead of a U.S. enterprise resource planning (ERP) deployment. This one-time surge is expected to negatively impact third-quarter sales as inventory levels normalize. Organic growth was strong across all segments, particularly in Dental Solutions (15.2%) and MedSurg (8.9%). However, total company operating income declined 15.8% to $181 million, largely due to increased corporate costs related to the ongoing separation from 3M and legal accruals. Management announced plans to pursue a separation of the Health Information Systems business to optimize the portfolio and enhance shareholder value. Financially, the company benefited from a $120 million IEEPA tariff refund recognized in the second quarter. Liquidity remains supported by cash on hand and access to a $2 billion commercial paper program, though cash from operations decreased year-over-year due to higher incentive compensation and transition-related payments. The company continues to execute a $1 billion share repurchase program, having bought back 3.9 million shares during the quarter. Key risks include ongoing inflationary pressures, tariff volatility, and the operational complexities of establishing a standalone corporate infrastructure. |
| May 5, 2026 | mda_quarterly | Solventum reported first-quarter 2026 net sales of $2.01 billion, a 3.0% reported decline but 2.1% organic growth. Total operating income fell 46.7% to $81 million, pressured by higher SG&A costs related to the 3M separation and the "Transform for the Future" restructuring program. The company recently completed the $4 billion sale of its Purification and Filtration business, while retaining its Water Business. MedSurg sales grew 6.6%, driven by Tegaderm CHG and negative pressure wound therapy, though operating income declined 21.8% due to tariffs and inflation. Dental Solutions saw a 7.9% sales increase led by restorative and prevention solutions, and Health Information Systems grew 4.1% through adoption of Solventum 360 Encompass and Performance Management Solutions. Liquidity tightened, with cash and equivalents falling to $561 million and operating cash flow turning negative at $189 million, primarily due to incentive compensation and 3M transition exit payments. A significant headwind remains the volatile tariff environment; while a Supreme Court ruling regarding the International Emergency Economic Powers Act may lead to future refunds, the company anticipates new tariffs in 2026. Additionally, the company spent $67 million on share repurchases during the quarter. |
Source: SEC EDGAR filing text and events; period Aug 5, 2026; filed Aug 5, 2026.
SOLV company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.